0 7 Vitamin Vitamin NNP 8 9 E E NNP 10 17 therapy therapy NN 18 20 of of IN 21 26 acute acute JJ 27 39 CCl4-induced ccl4-induced JJ 40 47 hepatic hepatic JJ 48 54 injury injury NN 55 57 in in IN 58 62 mice mouse NNS 63 65 is be VBZ 66 76 associated associate VBN 77 81 with with IN 82 92 inhibition inhibition NN 93 95 of of IN 96 103 nuclear nuclear JJ 104 110 factor factor NN 111 116 kappa kappa NN 117 118 B B NNP 119 126 binding binding NN 126 127 . . . 129 138 Oxidative oxidative JJ 139 145 stress stress NN 145 146 , , , 147 151 with with IN 152 160 reactive reactive JJ 161 167 oxygen oxygen NN 168 180 intermediate intermediate JJ 181 190 formation formation NN 190 191 , , , 192 195 may may MD 196 205 represent represent VB 206 207 a a DT 208 214 common common JJ 215 224 mechanism mechanism NN 225 227 by by IN 228 233 which which WDT 234 239 liver liver NN 240 246 injury injury NN 247 249 is be VBZ 250 257 induced induce VBN 258 260 by by IN 261 268 diverse diverse JJ 269 279 etiologies etiology NNS 279 280 . . . 281 290 Oxidative oxidative JJ 291 297 stress stress NN 298 306 enhances enhance VBZ 307 314 nuclear nuclear JJ 315 321 factor factor NN 322 327 kappa kappa NN 328 329 B B NNP 330 331 ( ( ( 331 339 NF-kappa NF-kappa NNP 340 341 B B NNP 341 342 ) ) ) 343 351 activity activity NN 351 352 , , , 353 356 and and CC 357 365 NF-kappa NF-kappa NNP 366 367 B B NNP 368 376 activity activity NN 377 380 has have VBZ 381 385 been be VBN 386 391 shown show VBN 392 394 to to TO 395 402 enhance enhance VB 403 406 the the DT 407 417 expression expression NN 418 420 of of IN 421 430 cytotoxic cytotoxic JJ 431 440 cytokines cytokine NNS 440 441 . . . 442 447 Acute acute JJ 448 455 hepatic hepatic JJ 456 462 injury injury NN 463 469 caused cause VBN 470 472 by by IN 473 481 reactive reactive JJ 482 488 oxygen oxygen NN 489 501 intermediate intermediate JJ 502 512 production production NN 513 516 was be VBD 517 524 induced induce VBN 525 527 by by IN 528 530 an an DT 531 546 intraperitoneal intraperitoneal JJ 547 556 injection injection NN 557 559 of of IN 560 564 CCl4 ccl4 NN 565 567 in in IN 568 572 mice mouse NNS 572 573 . . . 574 578 This this DT 579 585 injury injury NN 586 589 was be VBD 590 603 significantly significantly RB 604 613 inhibited inhibit VBN 614 616 by by IN 617 628 intravenous intravenous JJ 629 641 pretreatment pretreatment NN 642 644 of of IN 645 648 the the DT 649 653 mice mouse NNS 654 658 with with IN 659 660 a a DT 661 674 water-soluble water-soluble JJ 675 683 emulsion emulsion NN 684 686 of of IN 687 703 alpha-tocopherol alpha-tocopherol NN 703 704 . . . 705 721 Alpha-tocopherol Alpha-tocopherol NNP 722 731 treatment treatment NN 732 734 of of IN 735 738 the the DT 739 743 mice mouse NNS 744 749 given give VBN 750 753 the the DT 754 758 CCl4 ccl4 NN 759 763 also also RB 764 771 reduced reduce VBD 772 775 the the DT 776 784 NF-kappa NF-kappa NNP 785 786 B B NNP 787 794 binding bind VBG 795 797 to to TO 798 804 levels level NNS 805 816 approaching approach VBG 817 822 those those DT 823 828 found find VBN 829 831 in in IN 832 838 normal normal JJ 839 843 mice mouse NNS 843 844 . . . 845 847 In in FW 848 853 vitro vitro FW 854 863 treatment treatment NN 864 866 of of IN 867 868 a a DT 869 888 monocyte/macrophage monocyte/macrophage NN 889 893 cell cell NN 894 898 line line NN 899 903 with with IN 904 908 CCl4 ccl4 NN 909 912 led lead VBD 913 915 to to TO 916 924 enhanced enhance VBN 925 933 NF-kappa NF-kappa NNP 934 935 B B NNP 936 943 binding binding NN 944 947 and and CC 948 950 an an DT 951 959 increase increase NN 960 962 in in IN 963 968 tumor tumor NN 969 977 necrosis necrosis NN 978 990 factor-alpha factor-alpha NN 991 992 ( ( ( 992 1001 TNF-alpha TNF-alpha NNP 1001 1002 ) ) ) 1003 1012 messenger messenger NN 1013 1016 RNA RNA NNP 1017 1023 levels level NNS 1023 1024 . . . 1025 1030 Liver liver NN 1031 1040 specimens specimen NNS 1041 1046 taken take VBN 1047 1051 from from IN 1052 1060 patients patient NNS 1061 1065 with with IN 1066 1071 acute acute JJ 1072 1081 fulminant fulminant JJ 1082 1091 hepatitis hepatitis NN 1092 1095 had have VBD 1096 1104 markedly markedly RB 1105 1114 increased increase VBN 1115 1123 NF-kappa NF-kappa NNP 1124 1125 B B NNP 1126 1133 binding binding NN 1134 1142 activity activity NN 1143 1145 in in IN 1146 1156 comparison comparison NN 1157 1161 with with IN 1162 1165 the the DT 1166 1173 binding binding NN 1174 1176 of of IN 1177 1183 normal normal JJ 1184 1190 livers liver NNS 1190 1191 . . . 1192 1197 These these DT 1198 1202 data datum NNS 1203 1214 demonstrate demonstrate VBP 1215 1219 that that IN 1220 1230 abolishing abolish VBG 1231 1236 acute acute JJ 1237 1244 hepatic hepatic JJ 1245 1251 injury injury NN 1252 1256 with with IN 1257 1273 alpha-tocopherol alpha-tocopherol NN 1273 1274 , , , 1275 1276 a a DT 1277 1281 free free JJ 1282 1289 radical radical NN 1290 1299 scavenger scavenger NN 1299 1300 , , , 1301 1305 also also RB 1306 1316 eliminated eliminate VBD 1317 1326 increased increase VBN 1327 1335 NF-kappa NF-kappa NNP 1336 1337 B B NNP 1338 1345 binding binding NN 1345 1346 . . . 1347 1349 It it PRP 1350 1352 is be VBZ 1353 1361 tempting tempt VBG 1362 1364 to to TO 1365 1374 speculate speculate VB 1375 1379 that that IN 1380 1388 enhanced enhance VBN 1389 1397 NF-kappa NF-kappa NNP 1398 1399 B B NNP 1400 1410 expression expression NN 1411 1417 caused cause VBN 1418 1420 by by IN 1421 1425 free free JJ 1426 1433 radical radical NN 1434 1454 production/oxidative production/oxidative JJ 1455 1461 stress stress NN 1462 1465 may may MD 1466 1474 modulate modulate VB 1475 1480 liver liver NN 1481 1487 injury injury NN 1487 1488 , , , 1489 1496 perhaps perhaps RB 1497 1504 through through IN 1505 1507 an an DT 1508 1514 effect effect NN 1515 1517 on on IN 1518 1527 cytotoxic cytotoxic JJ 1528 1536 cytokine cytokine NN 1537 1546 synthesis synthesis NN 1546 1547 . . .